2023 French Cigarette Prices to Rise Due to Inflation

Dec.30.2022
2023 French Cigarette Prices to Rise Due to Inflation
French cigarette prices will rise due to inflation in 2023, according to the Prime Minster Elizabeth Borne.

Over the past two years, cigarette prices in France have remained largely stable. However, in 2023, prices are set to increase due to inflation. Earlier, French Prime Minister Elizabeth Borne revealed this information in an interview with BFMTV.


Following the approval of a cigarette price hike, according to the French Social Security Financing Act (PLFSS), it is expected that by 2023, the price of each pack of cigarettes in France will increase by 50 euro cents (approximately 3.44 Chinese yuan), and by 35 euro cents (approximately 2.4 Chinese yuan) in 2024, bringing the minimum price per pack to 11 euros (approximately 75.6 Chinese yuan).


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Malaysian Court Rules Liquid Nicotine Exemption Irrational, Renewing Vape Regulation Debate
Malaysian Court Rules Liquid Nicotine Exemption Irrational, Renewing Vape Regulation Debate
Malaysia’s High Court ruled that the government’s earlier decision to remove liquid nicotine from the country’s Poisons List was “irrational,” reigniting debate over vape regulation, illicit trade, and youth protection.
Regulations
May.18
 BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
British American Tobacco’s London-listed shares rose 13.99% last week, as investors focused on the U.S. Food and Drug Administration’s recent authorization of flavored Glas e-cigarette products, the dismissal of a U.S. sanctions-related criminal case against BAT, and the company’s previously announced share buyback plan and newer nicotine business performance.
BAT
May.18
 Zyn Emerges as MAGA Cultural Symbol Amid FDA Policy Shift
Zyn Emerges as MAGA Cultural Symbol Amid FDA Policy Shift
According to The Wall Street Journal, nicotine pouch brand Zyn has rapidly gained popularity across the Trump administration and conservative political circles, including among U.S. Health Secretary Robert F. Kennedy Jr.
Business
May.20
 BAT Bangladesh Cigarette Sales Fall 14%, Q1 Profit Drops 34%
BAT Bangladesh Cigarette Sales Fall 14%, Q1 Profit Drops 34%
British American Tobacco Bangladesh reported a 14% year-on-year decline in cigarette sales volume and a 34% drop in first-quarter profit, highlighting mounting pressure from inflation, taxation, and weakening consumer spending in Bangladesh.
News
May.18
Thailand’s DDC Files Complaint Over Online Sales of Nicotine Pouches
Thailand’s DDC Files Complaint Over Online Sales of Nicotine Pouches
Thailand’s Department of Disease Control has lodged a complaint over the alleged online sale of nicotine pouches. The department said its monitoring found the products were being advertised and sold through electronic media, and a further inquiry later identified a physical shop linked to a store in Pathum Thani province.
Mar.23 by 2FIRSTS.ai
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
Ahead of World No Tobacco Day 2026, WHO released its first global report on nicotine pouches, warning that rapid market growth, youth-oriented marketing and weak regulation are converging. 2Firsts views the report as an important warning, but not a complete risk assessment, with harm-reduction questions still unresolved.
Special Report
May.17